HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.

Abstract
Intrahepatic cholangiocarcinoma arising in chronic advanced liver disease sometimes contains a component of cholangiolocellular carcinoma. Bile duct adenoma, a benign tumor/tumorous lesion and ductular reaction, is also composed of bile ductular cells, and the differential diagnosis is sometimes difficult. We have previously reported that cholangiolocellular carcinoma showed overexpression of a polycomb group protein EZH2, which participates in bypass/escape from cellular senescence during carcinogenesis. In contrast, the ductular reaction showed high expression of senescence-associated p16(INK4a). In this study, we examined whether immunostaining for EZH2 and p16(INK4a) is useful for differential diagnosis among cholangiolocellular carcinoma, bile duct adenoma, and ductular reactions. Subjects included 33 patients with intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma with components of cholangiolocellular carcinoma and 16 patients with bile duct adenoma. The expressions of EZH2 and p16(INK4a) were examined immunohistochemically. The expression of EZH2 was seen in all cases of cholangiolocellular carcinomas, but it was not observed in bile duct adenomas and ductular reactions, which were seen around carcinomas in 80% of cases. The extensive expression of p16(INK4a) was seen only in 4 cases of cholangiolocellular carcinomas (12%). In contrast, the expression of p16(INK4a) was seen in 13 cases (81%) of bile duct adenomas and in all cases of ductular reactions. The borderline between the component of cholangiolocellular carcinoma and the surrounding ductular reaction was clearly highlighted by the reverse expression pattern of EZH2 and p16(INK4a) in 69% of cases. In conclusion, immunostaining for EZH2 and p16(INK4a) may be useful for differential diagnosis among cholangiolocellular carcinomas, bile duct adenomas, and ductular reactions.
AuthorsMotoko Sasaki, Takashi Matsubara, Yuko Kakuda, Yasunori Sato, Yasuni Nakanuma
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 38 Issue 3 Pg. 364-9 (Mar 2014) ISSN: 1532-0979 [Electronic] United States
PMID24487593 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase Inhibitor p16
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 2
Topics
  • Adenoma, Bile Duct (chemistry, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Bile Duct Neoplasms (chemistry, pathology)
  • Bile Ducts, Intrahepatic (chemistry, pathology)
  • Biomarkers, Tumor (analysis)
  • Biopsy
  • Cellular Senescence
  • Cholangiocarcinoma (chemistry, pathology)
  • Cyclin-Dependent Kinase Inhibitor p16 (analysis)
  • Diagnosis, Differential
  • Enhancer of Zeste Homolog 2 Protein
  • Female
  • Humans
  • Immunohistochemistry
  • Liver Neoplasms (chemistry, pathology)
  • Male
  • Middle Aged
  • Polycomb Repressive Complex 2 (analysis)
  • Predictive Value of Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: